ADC Therapeutics (ADC Therapeutics) EV-to-EBIT : -1.37 (As of Apr. 28, 2024)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ADC Therapeutics's Enterprise Value is $203.96 Mil. ADC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-148.53 Mil. Therefore, ADC Therapeutics's EV-to-EBIT for today is -1.37.

The historical rank and industry rank for ADC Therapeutics's EV-to-EBIT or its related term are showing as below:

ADCT' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.59 Med: -2.9 Max: 1.25
Current: -1.37

During the past 8 years, the highest EV-to-EBIT of ADC Therapeutics was 1.25. The lowest was -24.59. And the median was -2.90.

ADCT's EV-to-EBIT is ranked worse than
100% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs ADCT: -1.37

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ADC Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-17.61 Mil. ADC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-148.53 Mil. ADC Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 843.22%.

ADC Therapeutics EV-to-EBIT Historical Data

The historical data trend for ADC Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics EV-to-EBIT Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-8.54

-5.25

-0.91

0.12

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-0.91	0.20	0.38	0.89	0.12

Competitive Comparison of ADC Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, ADC Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADC Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's EV-to-EBIT falls into.

ADC Therapeutics EV-to-EBIT Calculation

ADC Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	203.957	/	-148.528
	=	-1.37

ADC Therapeutics's current Enterprise Value is $203.96 Mil.
ADC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.53 Mil.

ADC Therapeutics (NYSE:ADCT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ADC Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-148.528	/	-17.614454
	=	843.22 %

ADC Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-17.61 Mil.
ADC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.53 Mil.

ADC Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.